Gastroesophageal reflux disease

Current Opinion in Gastroenterology

Volumn 19, Issue 4, 2003, Pages 373-378

  Nguyen, Nam Q ^a   Holloway, Richard H ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; ALEMCINAL; BACLOFEN; ESOMEPRAZOLE; GABAERGIC RECEPTOR AFFECTING AGENT; GAMMA INTERFERON; HISTAMINE H2 RECEPTOR ANTAGONIST; INTERLEUKIN 1BETA; INTERLEUKIN 8; MOTILIN; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; RILUZOLE; STEROID;

ASTHMA; BARRETT ESOPHAGUS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; ENDOSCOPIC THERAPY; GASTROESOPHAGEAL REFLUX; HEALTH CARE SYSTEM; HELICOBACTER PYLORI; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; LOWER ESOPHAGUS SPHINCTER; NEUROPHYSIOLOGY; PATHOGENESIS; PATHOPHYSIOLOGY; REFLUX ESOPHAGITIS; REVIEW;

EID: 0038676299     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200307000-00009     Document Type: Review

References (43)

1. Manabe N, Haruma K, Mihara M, et al.: The increasing incidence of reflux esophagitis during the past 20 years in Japan. Gastroenterology 1999, 166:A244.
2. Spechler SJ, Jain SK, Tendler DA, et al.: Racial differences in the frequency of symptoms and complications of gastro-esophageal reflux disease. Aliment Pharmacol Ther 2002, 16:1795-1800.
3. Manabe N, Yoshihara M, Sasaki A, et al.: Clinical characteristics and natural history of patients with low grade reflux esophagitis. J Gastroenterol Hepatol 2002, 17:949-954. A well-conducted Eastern study confirming previous Western findings that the majority of patients with low-grade reflux esophagitis do well over a 5-year period.
4. Orenstein SR, Shalby TM, Barmada MM, et al.: Genetics of gastroesophageal reflux disease: a review. J Pediatr Gastroenterol Nutr 2002, 34:506-510.
5. Cameron AJ, Lagergren J, Henriksson C, et al.: Gastroesophageal reflux disease in monozygotic and dizygotic twins. Gastroenterology 2002, 122:55-59.
6. Fass R, Ofman JJ: Gastroesophageal reflux disease: should we adopt a new conceptual framework? Am J Gastroenterol 2002, 97:1901-1909. An interesting proposal for a new paradigm shift in the understanding of GERD after detailed literature reviews. This new concept may have both diagnostic and therapeutic implications.
7. Fass R: Gastroesophageal reflux disease revisited. Gastroenterol Clin North Am 2002, 31:S1-10.
8. Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, et al.: Diversity in the esophageal phenotypic response to gastroesophageal reflux: immunological determinants. Gut 2002, 50:451-459. This study demonstrated the importance of T-cell involvement and differentiation in determining the phenotypic outcome of GERD.
9. Liu B, Liu X, Tang C, et al.: Esophageal dysmotility and the change of synthesis of nitric oxide in a feline esophagitis model. Dis Esophagus 2002, 15:191-198.
10. Boeckxstaens GE, Tytget GNJ: More pathophysiologically oriented treatment of GORD? Lancet 2002, 359:1267-1268.
11. Hirsch DP, Tytgat GNJ, Boeckzstaens GEE: Transient lower esophageal sphincter relaxations: a pharmacological target for gastroesophageal reflux disease [review]. Aliment Pharmacol Ther 2002, 16:17-26. This is an excellent review on the neurophysiology of TLESRs with a therapeutic implication.
12. Zhang Q, Lehmann A, Rigda R, et al.: Control of transient lower esophageal sphincter relaxations and reflux by the GABAb agonist baclofen in patients with gastroesophageal reflux disease. Gut 2002, 50:19-24.
13. Van-Herwaarden MA, Samsom M, Rydholm H, et al.: The effect of baclofen on gastroesophageal reflux, lower esophageal sphincter function and reflux symptoms in patients with reflux disease. Aliment Pharmacol Ther 2002, 16:1655-1662.
14. Cange L, Johnsson E, Rydholm H, et al.: Baclofen-mediated gastroesophageal acid reflux control in patients with established reflux disease. Aliment Pharmacol Ther 2002, 16:869-873. These three small studies confirmed and consolidated the therapeutic role of GABA-β agonist in the management of GERD. However, larger clinical studies are needed prior to recommendation of its use in clinical setting.
15. Hirsch DP, Tytgat GNJ, Boeckzstaens GEE: Is glutamate involved in transient lower esophageal sphincter relaxations? Dig Dis Sci 2002, 47:661-666.
16. Pandolfino JE, Shi G, Curry J, et al.: Esophagogastric junction distensibility: a factor contributing to sphincter incompetence. Am J Physiol 2002, 282:G1052-G1058.
17. Vakil NB. Gastroesophageal reflux disease and Helicobacter pylori infection [review]. Aliment Pharmacol Ther 2002, 16(S):47-51. A detailed review on the controversies of the involvement of H. pylori in GERD and the effect of H. pylori eradication of GERD.
18. Malfertheiner P, O'Conner HJ, Genta RM, et al.: Symposium: Helicobacter pylori and clinical risks: focus on gastroesophageal reflux disease. Aliment Pharmacol Ther 2002, 16(S):1-10.
19. Malfertheiner P, Dent J, Zeijlon L, et al.: Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease: results from a randomized trial programme. Aliment Pharmacol Ther 2002, 16:1431-1442. A large randomized study demonstrated that eradication of H. pylori in a European population with peptic ulcer disease had no adverse effect on GERD.
20. Laine L, Dhir V: Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial. Aliment Pharmacol Ther 2002, 16:1143-1148.
21. Wu JCY, Chan FKL, Wong SKH, et al.: Effect of Helicobacter pylori eradication on esophageal acid exposure in patients with reflux esophagitis. Aliment Pharmacol Ther 2002, 16:545-552. In contrast to the recent Western findings, this Hong Kong study found an adverse effect of H. pylori eradication in Asian patients with GERD.
22. Lazenby JP, Guzzo MR, Harding SM, et al.: Oral corticosteroids increase esophageal acid contact times in patients with stable asthma. Chest 2002, 121:625-634. This is the first study to suggest that steroid therapy for asthma potentially can trigger and aggravate reflux disease in stable patients with asthma.
23. Irwin RS, Zawacki JK, Wilson MM, et al.: Chronic cough due to gastroesophageal reflux disease: failure to resolve despite total/near elimination of esophageal acid. Chest 2002, 121:1132-1140. This study suggested that nonacid reflux can contribute to chronic cough in asthma and antireflux surgery should be considered if maximal medical therapy failed to treat the chronic cough.
24. Gislason T, Janson C, Vermeire P, et al.: Respiratory symptoms and nocturnal gastroesophageal reflux: a population based study of young adults in 3 European countries. Chest 2002, 121:158-163. Another large populational study consolidates the link between respiratory diseases and GERD.
25. Valipour A, Makker HK, Hardy R, et al.: Symptomatic gastroesophageal reflux in subjects with a breathing sleep disorder. Chest 2002, 121:1748-1753.
26. Vantrappen G, Tack J, Huyberechts G, et al.: Studies on the relationship between esophageal acid exposure, mucosal lesions and heartburn using an acid exposure sensor. Scand J Gastroenterol 2002, 37:1253-1258. A preliminary study on a new diagnostic tool in GERD, with a good correlation with acid exposure and heartburn score.
27. 2RA should be used only as an adjunct therapy on an intermittent as-needed basis.
28. Netzer P, Schmitt B, Inauen W: Effects of ABT-229, a motilin agonist, on acid reflux, esophageal motility and gastric emptying in patients with gastroesophageal reflux disease. Aliment Pharmacol Ther 2002, 16:1481-1490.
29. Chen CL, Orr WC, Verlinden MH, et al.: Efficacy of a motilin receptor agonist (ABT-229) for the treatment of gastroesophageal reflux disease. Aliment Pharmacol Ther 2002, 16:749-757. A large randomized trial confirmed that the motilin receptor agonist (ABT-229) is not effective and has no role in the management of GERD.
30. DiBaise JK, Brand RE, Quigley EMM: Endoluminal delivery of radiofrequency energy to the gastroesophageal junction in uncomplicated GERD: efficacy and potential mechanism of action. Am J Gastroentero; 2002, 97:833-842.
31. Triadafilopoulos G, Dibaise JK, Nostrant TT, et al.: The Stretta procedure for the treatment of GERD: 6 and 12 month follow up of the US open label trial. Gastrointest Endosc 2002, 55:149-156. A large trial demonstrated that Stretta procedure is well tolerated and effectively improves heartburn symptoms as well as reducing PPI usage.
32. Filipi CJ, Lehman GA, Rothstein RI, et al.: Transoral, flexible endoscopic suturing for treatment of GERD: a multicenter trial. Gastrointest Endosc 2001, 53:416-422.
33. Velanovich V, Ben-Menachem T, Goel S: Case-control comparison of endosocopic gastroplication with laparoscopic fundoplication in the management of gastroesophageal reflux disease: early symptomatic outcomes. Surg Laparosc Endosc Percutan Tech 2002, 12:219-223.
34. Deviere J, Pastorelli A, Louis H, et al.: Endoscopic implantation of a biopolymer in the lower esophageal sphincter for gastroesophageal reflux: a pilot study. Gastrointest Endosc 2002, 55:335-341.
35. Booth MI, Jones L, Stratford J, et al.: Results of laparoscopic Nissen fundoplication at 2-8 years after surgery. Br J Surg 2002, 89:476-481.
36. Khajanchee YS, Urbach DR, Butler N, et al.: Laparoscopic antireflux surgery in the elderly: surgical outcome and effect on quality of life. Surg Endosc 2002, 16:25-30. Contrary to the traditional view of surgery in elderly patients, this prospective trial suggested the proactive role of laparosocopic antireflux surgery in elderly patients with severe GERD.
37. Leeder PC, Watson DL, Jamieson GG: Laparoscopic fundoplication for patients with symptoms but no objective evidence of gastroesophageal reflux. Dis Esophagus 2002, 15:309-314. This study emphasized that important of symptom assessment in GERD patients who plan for laparoscopic fundoplication. Even without objective evidence of GERD, patients with typical reflux symptoms may benefit from fundoplication.
38. O'Boyle CJ, Watson DI, DeBeaux AC, et al.: Pre-operative prediction of long term outcome following laparoscopic fundoplication. Aust N Z J Surg 2002, 72:471-475.
39. Booth M, Stratford J, Dehn TCB: Pre-operative esophageal body motility does not influence the outcome of laparoscopic Nissen fundoplication for gastroesophageal reflux disease. Dis Esophagus 2002, 15:57-60. Prospective data suggested that esophageal body motility has little impact on the outcome of taparoscopic fundoplication.
40. Vakil N. Cost effectiveness of different GERD management strategies [review]. Aliment Pharmacol Ther 2002, 16(S4):79-82. A good review on various strategies in the management of GERD, both acute and maintenance therapies.
41. Kleinman L, McIntosh E, Ryan M, et al.: Willingness to pay for complete symptom relief of gastroesophageal reflux disease. Arch Intern Med 2002, 162:1361-1366.
42. Ofman JJ, Dorn GH, Fennerty MB, et al.: The clinical and economic impact of competing management strategies for gastroesophageal reflux disease. Aliment Pharmacol Ther 2002, 16:261-271.
43. Wahlquist P, Junghard O, Higgins A, et al.: Cost effectiveness of proton pump inhibitors in gastroesophageal reflux disease without esophagitis. Pharmacoeconomics 2002, 20:267-277. A model analysis showed that it is cost-effective to treat the majority of patient with nonerosive reflux disease with on-demand PPI therapy.